


Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Approved for use through 10/31/2002. OMB 951-0031
US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/048,072
Filing Date	January 25, 2002
First Named Inventor	Franchini, Genoveffa
Group Art Unit	1648
Examiner Name	Parkin, Jeffrey

Sheet 1 of 1

Attorney Docket No: 1662.018US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date if Appropriate
--------------------	---------------------	------------------	---	----------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
---------------------	---------------------	------------------	---	----------------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
2		FRIEDRICH, T. , et al., "The rule of the SIV Model in AIDS vaccine research", <u>IAVI Report</u> , Vol. 9, No. 2, (June 14, 2005), 5 pages	
		HEL, Z. , "Improved Vaccine Protection from Simian AIDS by the Addition of Nonstructural Simian Immunodeficiency Virus Genes", <u>The Journal of Immunology</u> , 176, (2006), 85-96	
		HIRSCH, V. , "What can natural infection of African monkeys with simian immunodeficiency virus tell us about the pathogenesis of AIDS?", <u>AIDS Rev.</u> , 6(1), (Jan.-Mar., 2004), 40-53	
		LU, S. , et al., "Simian Immunodeficiency Virus DNA Vaccine", <u>Journal of Virology</u> , 70:6, 0022-538X/96/\$04.00+0, (June 1996), pp. 3978-3991	
		MUTHUMANI, K. , et al., "A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques", <u>Vaccine</u> , 21(7-8), (Jan. 30, 2003), 629-37	
		PHILIPP, M. T., et al., "Experimental infection of rhesus macaques with Streptococcus pneumoniae: a possible model for vaccine assessment", <u>J Med Primatol.</u> , 35(3), (June, 2006), 113-22	
		SAUTER, S. L., "Non-Replicating Viral Vector-Based AIDS Vaccines: Interplay Between Viral Vectors and the Immune System", <u>Current HIV research</u> , 3(2), (Apr., 2005), 157-181	
		SUN, W. , et al., "Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination", <u>J Infect Dis.</u> , 193(12), (June 15, 2006), 1658-65	

EXAMINER

DATE CONSIDERED 11/24/2006

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 806. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached